Timeline | Published:

RAS oncogenes: the first 30 years

Nature Reviews Cancer volume 3, pages 459465 (2003) | Download Citation

Subjects

  • A Correction to this article was published on 01 September 2003

Abstract

From the pioneering work with acute transforming retroviruses to the current post-genomic era, RAS genes have always been at the leading edge of signal transduction and molecular oncology. Yet, a complete understanding of RAS function and dysfunction — mainly in human cancer — is still to come. The knowledge that has accumulated since their discovery 30 years ago has, however, been remarkable, and should pave the way for not only solving the outstanding issues regarding RAS biology, but also for developing efficacious drugs that could have a significant impact on cancer treatment.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    An unidentified virus which causes the rapid production of tumors in mice. Nature 204, 1104–1105 (1964).

  2. 2.

    & Morphologic responses to a murine erythroblastosis virus. J. Natl Cancer Inst. 39, 311–335 (1967).

  3. 3.

    , , , & Naturally occurring sarcoma virus of the BALB/cCr mouse. J. Natl Cancer Inst. 53, 1725–1729 (1974).

  4. 4.

    , & In vitro isolation of stable rat sarcoma viruses. Proc. Natl Acad. Sci. USA 75, 2972–2976 (1978).

  5. 5.

    , , & Studies on the nucleic acid sequences of Kirsten sarcoma virus: a model for formation of a mammalian RNA-containing sarcoma virus. J. Virol. 12, 458–463 (1973).

  6. 6.

    et al. Molecular cloning of the Harvey sarcoma virus closed circular DNA intermediates: initial structural and biological characterization. J. Virol. 31, 795–809 (1979).

  7. 7.

    & Structure and functions of the Kirsten murine sarcoma virus genome: molecular cloning of biologically active Kirsten murine sarcoma virus DNA. J. Virol. 38, 720–727 (1981).

  8. 8.

    et al. The p21 src genes of Harvey and Kirsten murine sarcoma viruses originate from divergent members of a family of normal vertebrate genes. Nature 292, 506–511 (1981).

  9. 9.

    , , & Biochemical transfer of single-copy eucaryotic genes using total cellular DNA as donor. Cell 14, 725–731 (1978).

  10. 10.

    , , , & Passage of phenotypes of chemically transformed cells via transfection of DNA and chromatin. Proc. Natl Acad. Sci. USA 76, 5714–5718 (1979).

  11. 11.

    , , & Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 290, 261–264 (1981).

  12. 12.

    et al. Human-tumor-derived cell lines contain common and different transforming genes. Cell 27, 467–476 (1981).

  13. 13.

    & Isolation of a transforming sequence from a human bladder sarcoma cell line. Cell 29, 161–169 (1982).

  14. 14.

    , , & Isolation and preliminary characterization of a human transforming gene from T24 bladder carcinoma cells. Nature 296, 404–409 (1982).

  15. 15.

    et al. Oncogenes in human tumor cell lines: molecular cloning of a transforming gene from human bladder carcinoma cells. Proc. Natl Acad. Sci. USA 79, 2845–2849 (1982).

  16. 16.

    , & Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc. Natl Acad. Sci. USA 79, 3637–3640 (1982).

  17. 17.

    , , & Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras. Nature 297, 474–478 (1982).

  18. 18.

    , , , & T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes. Nature 298, 343–347 (1982).

  19. 19.

    & Presence of a Kirsten murine sarcoma virus ras oncogene in cells transformed by 3-methylcholanthrene. Mol. Cell. Biol. 3, 2298–2301 (1983).

  20. 20.

    , , & Isolation and preliminary characterization of the transforming gene of a human neuroblastoma cell line. Proc. Natl Acad. Sci. USA 80, 383–387 (1983).

  21. 21.

    , , & Identification of transforming gene in two human sarcoma cell lines as a new member of the ras gene family located on chromosome 1. Nature 303, 396–400 (1983).

  22. 22.

    , , & A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature 300, 149–152 (1982).

  23. 23.

    et al. Mechanism of activation of a human oncogene. Nature 300, 143–147 (1982).

  24. 24.

    et al. Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change. Nature 300, 762–765 (1982).

  25. 25.

    , , , & The human c-ras1H oncogene: a mutation in normal and neoplastic tissue from the same patient. Science 219, 853–856 (1983).

  26. 26.

    Activated proto-onc genes: sufficient or necessary for cancer? Science 228, 669–677 (1985).

  27. 27.

    , & Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304, 596–602 (1983).

  28. 28.

    & Fibroblast immortality is a prerequisite for transformation by EJ c-Ha-ras oncogene. Nature 304, 648–651 (1983).

  29. 29.

    Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture. Nature 304, 602–606 (1983).

  30. 30.

    et al. Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science 223, 661–664 (1984).

  31. 31.

    ras oncogenes in human cancer: a review. Cancer Res. 49, 4682–4689 (1989).

  32. 32.

    et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 327, 293–297 (1987).

  33. 33.

    , , , & Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 327, 298–303 (1987).

  34. 34.

    et al. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N. Engl. J. Med. 317, 929–935 (1987).

  35. 35.

    et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53, 549–554 (1988).

  36. 36.

    & Mouse skin carcinomas induced in vivo by chemical carcinogens have a transforming Harvey-ras oncogene. Nature 303, 72–74 (1983).

  37. 37.

    , , & Induction of mammary carcinomas in rats by nitroso-methyl-urea involves the malignant activation of the H-ras-1 locus by single point mutations. Nature 306, 658–661 (1983).

  38. 38.

    , , & A molecular approach to leukemogenesis: mouse lymphomas contain an activated c-ras oncogene. Proc. Natl Acad. Sci. USA 81, 202–205 (1984).

  39. 39.

    & In vitro translation of Harvey murine sarcoma virus RNA. J. Virol. 22, 711–719 (1977).

  40. 40.

    , , & p21 of Kirsten murine sarcoma virus is thermolabile in a viral mutant temperature sensitive for the maintenance of transformation. J. Virol. 31, 546–546 (1979).

  41. 41.

    , , & Identification of a sarcoma virus-coded phosphoprotein in nonproducer cells tranformed by Kirsten or Harvey murine sarcoma virus. Virology 96, 64–79 (1979).

  42. 42.

    , & Guanine nucleotide-binding activity as an assay for src protein of rat-derived murine sarcoma viruses. Proc. Natl Acad. Sci. USA 76, 5355–5359 (1979).

  43. 43.

    , , & Localization of the src gene product of the Harvey strain of MSV to plasma membrane of transformed cells by electron microscopic immunocytochemistry. Cell 19, 1005–1014 (1980).

  44. 44.

    , , , & The p21ras c-terminus is required for transformation and membrane association. Nature 310, 583–586 (1984).

  45. 45.

    , , & Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules. Proc. Natl Acad. Sci. USA 81, 5704–5708 (1984).

  46. 46.

    , , & Comparative biochemical properties of normal and activated human ras p21 protein. Nature 310, 644–649 (1984).

  47. 47.

    et al. The product of ras is a GTPase and the T24 oncogenic mutant is deficient in this activity. Nature 311, 273–275 (1984).

  48. 48.

    , , , & Homologies between signal transducing G proteins and ras gene products. Science 226, 860–862 (1984).

  49. 49.

    et al. In yeast, RAS proteins are controlling elements of adenylate cyclase. Cell 40, 27–36 (1985).

  50. 50.

    & Epidermal growth factor stimulates guanine nucleotide binding activity and phosphorylation of ras oncogene proteins. Nature 310, 147–150 (1984).

  51. 51.

    , & Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells. Nature 313, 241–243 (1985).

  52. 52.

    , & Requirement for c-Ras proteins during viral oncogene transformation. Nature 320, 540–543 (1986).

  53. 53.

    , & ras proteins can induce meiosis in Xenopus oocytes. Cell 43, 615–621 (1985).

  54. 54.

    & A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science 238, 542–545 (1987).

  55. 55.

    et al. Molecular cloning of two types of GAP complementary DNA from human placenta. Science 242, 1697–1700 (1988).

  56. 56.

    et al. Cloning of bovine GAP and its interaction with oncogenic ras p21. Nature 335, 90–93 (1988).

  57. 57.

    et al. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 63, 851–859 (1990).

  58. 58.

    et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 63, 843–849 (1990).

  59. 59.

    et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 249, 181–186 (1990).

  60. 60.

    et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 62, 599–608 (1990).

  61. 61.

    et al. The S. cerevisiae CDC25 gene product regulates the RAS/adenylate cyclase pathway. Cell 48, 789–799 (1987).

  62. 62.

    , , , & CDC25: a component of the RAS-adenylate cyclase pathway in Saccharomyces cerevisiae. Science 235, 1218–1221 (1987).

  63. 63.

    & A cytosolic protein catalyzes the release of GDP from p21ras. Science 248, 67–69 (1990).

  64. 64.

    , , & Identification of a nucleotide exchange-promoting activity for p21ras. Proc. Natl Acad. Sci. USA 87, 5998–6002 (1990).

  65. 65.

    et al. Cloning by functional complementation of a mouse cDNA encoding a homologue of CDC25, a Saccharomyces cerevisiae RAS activator. EMBO J. 11, 2151–2157 (1992).

  66. 66.

    , , & Identification of murine homologues of the Drosophila son of sevenless gene: potential activators of ras. Proc. Natl Acad. Sci. USA 89, 6511–6515 (1992).

  67. 67.

    , , & Molecular cloning of cDNAs encoding a guanine-releasing factor for ras p21. Nature 358, 351–354 (1992).

  68. 68.

    et al. Identification of a mammalian gene structurally and functionally related to the CDC25 gene of Saccharomyces cerevisiae. Proc. Natl Acad. Sci. USA 89, 7100–7104 (1992).

  69. 69.

    , & C. elegans cell-signalling gene Sem-5 encodes a protein with SH2 and SH3 domains. Nature 356, 340–344 (1992).

  70. 70.

    et al. The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to Ras signalling. Cell 70, 431–442 (1992).

  71. 71.

    , , & Cloning of ASH, a ubiquitous protein composed of one Src homology region (SH) 2 and two SH3 domains, from human and rat cDNA libraries. Proc. Natl Acad. Sci. USA 89, 9015–9019 (1992).

  72. 72.

    Signal transduction. How receptors turn Ras on. Nature 363, 15–16 (1993).

  73. 73.

    & Generation of oncogenic mouse type C viruses: in vitro selection of carcinoma-inducing variants. Proc. Natl Acad. Sci. USA 77, 624–628 (1980).

  74. 74.

    , , & Complexes of Ras. GTP with Raf-1 and mitogen-activated protein kinase kinase. Science 260, 1658–1661 (1993).

  75. 75.

    , & Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro. Nature 364, 352–355 (1993).

  76. 76.

    et al. Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1. Nature 364, 308–313 (1993).

  77. 77.

    , & Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell 74, 205–214 (1993).

  78. 78.

    , , & C. elegans lin-45 raf gene participates in let-60 ras-stimulated vulval differentiation. Nature 363, 133–140 (1993).

  79. 79.

    , , & Association of p21ras with phosphatidylinositol 3-kinase. Proc. Natl Acad. Sci. USA 88, 7908–7912 (1991).

  80. 80.

    Receptor tyrosine kinases and their targets. Curr. Opin. Genet. Dev. 4, 5–14 (1994).

  81. 81.

    et al. Phosphatidylinositol-3-OH kinase as a direct target for ras. Nature 370, 527–532 (1994).

  82. 82.

    , , & Activated Ras interacts with the Ral guanine nucleotide dissociation stimulator. Proc. Natl Acad. Sci. USA 91, 11089–11093 (1994).

  83. 83.

    , , , & ralGDS family members interact with the effector loop of ras p21. Mol. Cell. Biol. 14, 7483–7491 (1994).

  84. 84.

    & Identification of the guanine nucleotide dissociation stimulator for Ral as a putative effector molecule of R-ras, H-ras, K-ras, and Rap. Proc. Natl Acad. Sci. USA 91, 12609–12613 (1994).

  85. 85.

    et al. Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans. Science 245, 379–385 (1989).

  86. 86.

    et al. Enzymatic coupling of cholesterol intermediates to a mating pheromone precursor and to the ras protein. Science 249, 1133–1139 (1990).

  87. 87.

    , , , & Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides. Cell 62, 81–88 (1990).

  88. 88.

    et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nature Med. 1, 792–797 (1995).

  89. 89.

    , , , & Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res. 55, 5310–5314 (1995).

  90. 90.

    Targeting RAS signalling pathways in cancer therapy. Nature Rev. Cancer 3, 11–22 (2003).

  91. 91.

    et al. Three-dimensional structure of an oncogene protein: catalytic domain of human c-H-ras p21. Science 239, 888–893 (1988).

  92. 92.

    et al. Structure of the guanine-nucleotide-binding domain of the Ha-ras oncogene product p21 in the triphosphate conformation. Nature 341, 209–214 (1989).

  93. 93.

    et al. Time-resolved X-ray crystallographic study of the conformational change in Ha-Ras p21 protein on GTP hydrolysis. Nature 345, 309–315 (1990).

  94. 94.

    et al. Three-dimensional structures of H-ras p21 mutants: molecular basis for their inability to function as signal switch molecules. Cell 62, 539–548 (1990).

  95. 95.

    , , & Crystal structures at 2.2 Å resolution of the catalytic domains of normal ras protein and an oncogenic mutant complexed with GDP. J. Mol. Biol. 217, 503–516 (1991).

  96. 96.

    et al. The Ras-RasGAP complex: structural basis for GTPase activation and itss loss in oncogenic Ras mutants. Science 277, 333–338 (1997).

  97. 97.

    et al. Guanosine triphosphatase stimulation of oncogenic Ras mutants. Proc. Natl Acad. Sci. USA 96, 7065–7070 (1999).

  98. 98.

    et al. The structural basis of the activation of Ras by Sos. Nature 394, 337–343 (1998).

  99. 99.

    , , & Structural basis for the interaction of Ras with RalGDS. Nature Struct. Biol. 5, 422–426 (1998).

  100. 100.

    et al. Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell 103, 931–943 (2000).

  101. 101.

    & The Ras branch of small GTPases: Ras family members don't fall far from the tree. Curr. Opin. Cell Biol. 12, 157–165 (2000).

  102. 102.

    et al. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev. 11, 2468–2481 (1997).

  103. 103.

    et al. K-ras is essential for the development of the mouse embryo. Oncogene 15, 1151–1159 (1997).

  104. 104.

    et al. Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development. Mol. Cell. Biol. 21, 1444–1452 (2001).

  105. 105.

    & Ras pathway signaling on endomembranes. Curr. Opin. Cell Biol. 15, 136–142 (2003).

  106. 106.

    et al. Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev. 16, 2045–2057 (2002).

  107. 107.

    et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002).

  108. 108.

    , , & Activation of the mouse cellular Harvey-ras gene in chemically induced benign skin papillomas. Nature 307, 658–660 (1984).

  109. 109.

    , , , & Direct mutagenesis of H-ras-1 oncogenes by N-nitroso-N-methylurea during initiation of mammary carcinogenesis in rats. Nature 315, 382–385 (1985).

  110. 110.

    , , , & Activating mutations of the c-Ha-ras protooncogene in chemically induced hepatomas of the male B6C3 F1 mouse. Proc. Natl Acad. Sci. USA 83, 5825–5829 (1986).

  111. 111.

    et al. Essential role for oncogenic Ras in tumour maintenance. Nature 400, 468–472 (1999).

  112. 112.

    et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 15, 3249–3262 (2001).

  113. 113.

    et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410, 1111–1116 (2001).

  114. 114.

    et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15, 3243–3248 (2001).

  115. 115.

    , , , , & Coexpression of MMTV/v-Ha-ras and MMTV/ c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell 49, 465–475 (1987).

  116. 116.

    , , , & Pancreatic neoplasia induced by ras expression in acinar cells of transgenic mice. Cell 48, 1023–1034 (1987).

  117. 117.

    , , & The murine N-ras gene is not essential for growth and development. Proc. Natl Acad. Sci. USA 92, 1709–1713 (1995).

  118. 118.

    , et al. Mice deficient for N-ras: impaired antiviral immune response and T-cell function. Cancer Res. 63, 1615–1622 (2003).

  119. 119.

    et al. Targeted deletion of the H–ras gene decreases tumor formation in mouse skin carcinogenesis. Oncogene 19, 2951–2956 (2000).

Download references

Author information

Affiliations

  1. Marcos Malumbres and Mariano Barbacid are members of the Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Melchor Fernández Almagro 3, 28029 Madrid, Spain.

Authors

  1. Search for Marcos Malumbres in:

  2. Search for Mariano Barbacid in:

Corresponding authors

Correspondence to Marcos Malumbres or Mariano Barbacid.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrc1097

Further reading